Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials

References

• Kenemans P, Speroff L. International Tibolone Consensus Group. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005;51:21–28.
   PubMed Web of Science ®Google Scholar
• de Gooyer ME, Kleyn GT, Smits KC, Ederveen AG, Verheul HA, Kloosterboer HJ. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol 2001;183:55–62.
   PubMed Web of Science ®Google Scholar
• Rymer J, Chapman MG, Fogelman I, Wilson PO. A study of the effect of tibolone on the vagina in postmenopausal women. Maturitas 1994;18:127–133.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Ferdeghini F, Sampaolo P, Vaccaro P, De Leonardis C, Albani F, Salonia A, Polatti F. Clitoral circulation in postmenopausal women with sexual dysfunction: a pilot randomized study with hormone therapy. Maturitas 2006;55:288–295.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Sasano H, Andersson S, Mason JI. 3β-Hydroxysteroid dehydrogenase/delta5–>4-isomerase activity associated with the human 17β-hydroxysteroid dehydrogenase type 2 isoform. J Clin Endocrinol Metab 2000;85:3669–3672.
   PubMed Web of Science ®Google Scholar
• de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids 2003;68:21–30.
   PubMed Web of Science ®Google Scholar
• Nijland EA, Weijmar Schultz WC, Nathorst-Boös J, Helmond FA, Van Lunsen RH, Palacios S, Mulder RJ, Davis SR; LISA study investigators. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med 2008;5:646–656.
   PubMed Web of Science ®Google Scholar
• Bots ML, Evans GW, Riley W, McBride KH, Paskett ED, Helmond FA, Grobbee DE; OPAL Investigators. The effect of tibolone and continuous combined conjugated equine estrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tibolone (OPAL) study. Eur Heart J 2006;27:746–755.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, et al The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697–708.
   PubMed Web of Science ®Google Scholar
• Archer DF, Hendrix S, Gallagher JC, Rymer J, Skouby S, Ferenczy A, den Hollander W, Stathopoulos V, Helmond FA. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92:911–918.
   PubMed Web of Science ®Google Scholar
• Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, et al Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135–146.
   PubMed Web of Science ®Google Scholar
• Doren M, Rubig A, Coelnigh Bennink HJ, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 2001;75:554–559.
   PubMed Web of Science ®Google Scholar
• Davis SR. The effects of tibolone on mood and libido. Menopause 2002;9:162–170.
   PubMed Web of Science ®Google Scholar
• Pluchino N, Genazzani AD, Bernardi F, Casarosa E, Pieri M, Palumbo M, Picciarelli G, Gabbanini M, Luisi M, Genazzani AR. Tibolone, transdermal estradiol or oral estrogen–progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels. Gynecol Endocrinol 2005;20:144–149.
   PubMed Web of Science ®Google Scholar
• Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002;87:16–23.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Sances G, Sommacal A, Detaddei S, Facchinetti F, Cristina S, Polatti F, Nappi G. Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches. Menopause 2006;13:818–825.
   PubMed Web of Science ®Google Scholar
• Swanson SG, Drosman S, Helmond FA, Stathopoulos VM. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. Menopause 2006;13:917–925.
   PubMed Web of Science ®Google Scholar
• Palacios S, Menendez C, Jurado AR, Castano R, Vargas JC. Changes in sex behaviour after menopause: effects of tibolone. Maturitas 1995;22:155–161.
   PubMed Web of Science ®Google Scholar
• Nathorst-Boos J, Hammar M. Effect on sexual life – a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 1997;26:15–20.
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Vicente JJ, Figueras F, Sanjuan A, Martinez de Osaba MJ, Casals E, Pons F, Pons F, Balasch J, Vanrell JA. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000;34:161–168.
   PubMed Web of Science ®Google Scholar
• Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric 2001;4:28–41.
   PubMedGoogle Scholar
• Somunkiran A, Erel CT, Demirci F, Senturk ML. The effect of tibolone versus 17β-estradiol on climacteric symptoms in women with surgical menopause: a randomized, cross-over study. Maturitas 2007;56:61–68.
   PubMed Web of Science ®Google Scholar
• Soliman NF, Hillard TC. Hormone replacement therapy in women with past history of endometriosis. Climacteric 2006;9:325–335.
   PubMed Web of Science ®Google Scholar
• Nijland EA, Weijmar Schultz WC, Davis SR. Effects of tibolone and raloxifene on health-related quality of life and sexual function. Maturitas 2007;58:164–173.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Polatti F. The use of estrogen therapy in women's sexual functioning (CME). J Sex Med 2009;6:603–616; quiz 618–619.
   PubMed Web of Science ®Google Scholar
• Nijland EA, Nathorst-Böös J, Palacios S, van de Weijer PW, Davis S, Stathopoulos VM, Birkhaeuser MH, von Mauw E, Mulder RJ, Schultz WC, et al Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. Climacteric 2009;12:114–121.
   PubMed Web of Science ®Google Scholar
• Ederveen AG, Kloosterboer HJ. Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. J Bone Miner Res 2001;16:1651–1657.
   PubMed Web of Science ®Google Scholar
• Langer RD, Landgren BM, Rymer J, Helmond FA, OPAL Investigators. The OPAL study: BMD data from a three-year, double-blind, randomized study comparing the effects of tibolone, CEE/MPA and placebo in postmenopausal women. Menopause 2003;10:586.
   Web of Science ®Google Scholar
• Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women; results of two-randomised, double-blind, placebo-controlled, dose finding studies. J Clin Endocrinol Metab 2001;86:4717–4726.
   PubMed Web of Science ®Google Scholar
• Rymer J, Robinson J, Fogelman I. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric 2002;5:390–398.
   PubMed Web of Science ®Google Scholar
• Delmas PD, Davis SR, Hensen J, Adami S, van Os S, Nijland EA. Effects of tibolone and raloxifene on bone mineral density on osteopenic postmenopausal women. Osteoporos Int 2008;19:1153–1160.
   PubMed Web of Science ®Google Scholar
• Lindsay PC, Shaw RW, Coelingh Bennink HJ, Kovic P. The effect of add back treatment with tibolone (Livial®) on patients treated with the gonadotrophin-releasing hormone agonist triptorelin (Decapeptyl). Fertil Steril 1996;65:342–348.
   PubMed Web of Science ®Google Scholar
• Roux C, Pelissier C, Fechtenbaum J, Loiseau-Peres S, Benhamou CL. Randomized, double-blind, 2-year comparison of tibolone with 17β-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporosis Int 2002;13:241–248.
   PubMed Web of Science ®Google Scholar
• Lippuner K, Haenggi W, Birkhauser MH, Casez J-P, Jaeger P. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17β-oestradiol and dydrogesterone. J Bone Miner Res 1997;12:806–812.
   PubMed Web of Science ®Google Scholar
• Geusens P, Dequeker J, Gielen J, Schot LPC. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD14) in women with established osteoporosis. Maturitas 1991;13:155–162.
   PubMed Web of Science ®Google Scholar
• Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005;20:1912–1920.
   PubMed Web of Science ®Google Scholar
• Sumino H, Ichikawa S, Kasama S, Takahashi T, Kumakura H, Takayama Y, Kanda T, Sakamaki T, Kurabayashi M. Elevated arterial stiffness in postmenopausal women with osteoporosis. Maturitas 2006;55:212–218.
   PubMed Web of Science ®Google Scholar
• Ness J, Aronow WS. Comparison of prevalence of atherosclerotic vascular disease in postmenopausal women with osteoporosis or osteopenia versus without osteoporosis or osteopenia. Am J Cardiol 2006;97:1427–1428.
   PubMed Web of Science ®Google Scholar
• Koh KK, Jeong AJ, Jin DK, Yoon B-K, Kim HS, Kim DS, et al Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1889–1894.
   PubMed Web of Science ®Google Scholar
• Koh KK, Han SH, Shin M-S, Ahn JY, Lee Y, Shin EK. Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study. Eur Heart J 2005;26:1362–1368.
   PubMed Web of Science ®Google Scholar
• Prelevic GM, Kwong P, Byrne DJ, Jagroop IA, Ginsburg J, Mikhailidis DP. A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002;77:945–951.
   PubMed Web of Science ®Google Scholar
• Eilertsen AL Sandvik L, Steinsvik B, Sandset PM. Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. J Thromb Haemost 2008;6:928–934.
   PubMed Web of Science ®Google Scholar
• Sezer Ozer K, Erenus M, Yoldemir T. The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor-α and hepatocyte growth factor in postmenopausal women. Climacteric 2009;12:66–71.
   PubMed Web of Science ®Google Scholar
• Vural P, Canbaz M, Akgul C. Effects of menopause and postmenopausal tibolone treatment on plasma TNFα, IL-4, IL-10, IL-12 cytokine pattern and some bone turnover markers. Pharmacol Res 2006;53:367–371.
   PubMed Web of Science ®Google Scholar
• Zandberg P, Peters JLM, Demacker PNM, Smit MJ, de Reeder EG, Meuleman DG. Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovariectomized rabbits. Arterioscler Thromb Vasc Biol 1998;18:1844–1854.
   PubMed Web of Science ®Google Scholar
• Clarkson TB, Anthony MS, Cline JM, Lees CZ, Ederveen AGH. Multisystem evaluations of the long-term effects of tibolone on postmenopausal monkeys. Maturitas 2004;48 (Suppl 1):S24–S29.
   PubMed Web of Science ®Google Scholar
• von Eckardstein A, Schmiddem K, Hovels A, Gulbahce E, Schuler-Luttman S, Elbers J, Helmond F, Bennink HJ, Assmann G. Lowering of HDL cholesterol in post-menopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity. Atherosclerosis 2001;159:433–439.
   PubMed Web of Science ®Google Scholar
• Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Garibaldi S, Genazzani AR. Tibolone activates nitric oxide synthesis in human endothelial cells. J Clin Endocrinol Metab 2004;89:4594–4600.
   PubMed Web of Science ®Google Scholar
• Cicinelli E, Ignarro LJ, Galantino P, Pinto V, Barba B, Schonauer S. Effects of tibolone on plasma levels of nitric oxide in postmenopausal women. Fertil Steril 2002;78:464–468.
   PubMed Web of Science ®Google Scholar
• Simoncini T, Genazzani AR. Tibolone inhibits leukocyte adhesion molecule expression in human endothelial cells. Mol Cell Endocrinol 2000;162:87–94.
   PubMed Web of Science ®Google Scholar
• Cicinelli E, Ranieri G, Maffei S, Colafiglio G, Ria R, Bellavia M, Schonauer MM. Long-term effects of tibolone on circulating levels of vascular cell adhesion molecules and E-selectin in postmenopausal women. Fertil Steril 2006;86:899–904.
   PubMed Web of Science ®Google Scholar
• Sator K, Sator MO, Sator PG, Egarter C, Huber JC. Effects of tibolone on selectins in postmenopausal women. Maturitas 2006;53:166–170.
   PubMed Web of Science ®Google Scholar
• Carranza-Lira S, Cuan-Martínez JR, Rosales-Ortíz S. Brachial artery responses in menopausal women using tibolone. Int J Gynaecol Obstet 2008;101:43–46.
   PubMed Web of Science ®Google Scholar
• De Kleijn MJ, Wilmink HW, Bots ML, Bak AA, Van Der Schouw YT, Planellas J, Engelen S, Banga JD, Grobbee DE. Hormone replacement therapy and endothelial function: results of a randomized controlled trial in healthy postmenopausal women. Atherosclerosis 2001;159:357–365.
   PubMed Web of Science ®Google Scholar
• Silvestri A, Gambacciani M, Vitale C, Monteleone P, Ciaponi M, Fini M, Genazzani AR, Mercuro G, Rosano GM. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas 2005;50:305–311.
   PubMed Web of Science ®Google Scholar
• Erenus M, Ilhan AH, Elter K. Effect of tibolone treatment on intima-media thickness and the resistive indices of the carotid arteries. Fertil Steril 2003;79:268–273.
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Garcia-Fantini M, Haya J. Vascular reactivity and atheromatous plaques in postmenopausalwomen on tibolone treatment: open prospective study with Doppler ultrasonography in internal carotid artery. Maturitas 2005;50:259–265.
   PubMed Web of Science ®Google Scholar
• Clarkson TB. Does tibolone exacerbate atherosclerosis? Eur Heart J 2006;27:635–637.
   PubMed Web of Science ®Google Scholar
• Campisi R, Camilletti J, Mele, A, Erriest J, Pedroni P, Guiglioni A. Tibolone improves myocardial perfusion in postmenopausal women with ischemic heart disease: an open-label exploratory pilot study. J Am Coll Cardiol 2006;47:559–564.
   PubMed Web of Science ®Google Scholar
• Eilertsen AL, Qvigstad E, Andersen TO, Sandvik L, Sandset PM. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. Maturitas 2006;55:278–287.
   PubMed Web of Science ®Google Scholar
• Winkler UH. Effects of androgens on haemostasis. Maturitas 1996;24:147–155.
   PubMed Web of Science ®Google Scholar
• Winkler UH, Altkemper R, Kwee B, Helmond FA, Coelingh Bennink HJ. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double blind, randomized study. Fertil Steril 2000;74:10–19.
   PubMed Web of Science ®Google Scholar
• Speroff L, Clarkson TB. Cover story: is tibolone a viable alternative to HT? Contemporary Ob/Gyn 2003;48:54–68.
   Google Scholar
• Skouby SO, Sidelmann JJ, Nilas L, Gram J, Jespersen J. The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors. Climacteric 2008;11:489–497.
   PubMed Web of Science ®Google Scholar
• Løkkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard, Ø. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008;29:2660–2668.
   PubMed Web of Science ®Google Scholar
• de Vries CS, Bromley SE, Farmer RD. Myocardial infarction risk and hormone replacement: differences between products. Maturitas. 2006;53:343–350.
   PubMed Web of Science ®Google Scholar
• Winkler UH, Altkemper R, Kwee B, Helmond FA, Coelingh Bennink HJ. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 2000;74:10–19.
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637–645.
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:21–33.
   Web of Science ®Google Scholar
• Renoux C, Dell'aniello S, Garbe E, Suissa S. Hormone replacement therapy use and the risk of stroke. Maturitas 2008;61:305–309.
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–1712.
   PubMed Web of Science ®Google Scholar
• Banks E, Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419–427.
   PubMed Web of Science ®Google Scholar
• Opatrny L, Dell'Aniello S, Assouline S, Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 2008;115:169–175.
   PubMed Web of Science ®Google Scholar
• Hersh AL, Stefanik ML, Stafford RS. National use of postemenopausal hormone therapy. JAMA 2004;291:47–53.
   PubMed Web of Science ®Google Scholar
• Lawton B, Rose Mc Leod D, Dowell A. Changes in use of hormone replacement thearpy after the report from the Women's Health Initiative (WHI): cross sectional survey of users. BMJ 2003;327;845–846.
   PubMed Web of Science ®Google Scholar
• Chetrite G, Kloosterboer JR. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res 1997;17:135–140.
   PubMed Web of Science ®Google Scholar
• de Gooyer ME, Kleyn GT, Smits KC, Ederveen AG, Verheul HA, Kloosterboer HJ. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol 2001;183:55–62.
   PubMed Web of Science ®Google Scholar
• Notelovitz M. Postmenopausal tibolone therapy: biologic principles and applied clinical practice. Med Gen Med 2007;9:2.
   PubMedGoogle Scholar
• Valdivia I, Campodonico I, Tapia A, Capetillo M, Espinoza A, Lavín P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 2004;81:617–623.
   PubMed Web of Science ®Google Scholar
• Huber J, Palacios S, Berglund L, Hänggi W, Sathanandan SM, Christau S, Helmond F. The effect of tibolone compared with conjugated equine oestrogens continuously combined with medroxyprogesterone acetate on bleeding rates, quality of life and tolerability in postmenopausal women. Br J Obstet Gynaecol 2002;109:886–893.
   Google Scholar
• Shapiro S. The Million Women Study: potential biases do not allow uncritical acceptance of the data. Climacteric 2004;7:3–7.
   PubMed Web of Science ®Google Scholar
• Whitehead M, Farmer R. The MillionWomen Study: a critique. Endocrine 2004;24:187–194.
   PubMed Web of Science ®Google Scholar
• Hammar M, Christau S, Nathorst-Böös J, Rud T, Garre K. A double-blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998;105:904–911.
   PubMedGoogle Scholar
• Hammar M, van de Weijer P, Franke HR, Pornel B, von Mauw EM, Nijland EA, TOTAL Study Investigators Group. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy, tolerability. BJOG 2007;114:1522–1529.
   PubMed Web of Science ®Google Scholar
• Langer RD, Landgren BM, Rymer J, Helmond FA, OPAL Investigators. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. Am J Obstet Gynecol 2006;195:1320–1327.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, et al Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350:991–1004.
   PubMed Web of Science ®Google Scholar
• Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001;19:2357–2363.
   PubMed Web of Science ®Google Scholar
• Holmberg L, Anderson H, HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer –is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453–455.
   PubMed Web of Science ®Google Scholar
• Hickey M, Saunders CM, Stuckey BGA. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. Lancet Oncol 2005;6:687–695.
   PubMed Web of Science ®Google Scholar
• Dimitrakakis C, Keramopoulos D, Vourli G, Gaki V, Bredakis N, Keramopoulos A. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer. Climacteric 2005;8:342–351.
   PubMed Web of Science ®Google Scholar
• Kroiss R, Fentiman IS, Helmond FA, Rymer J, Folidart JM, Bundred N, Mol-Arts M, Kubista E. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. Br J Obstet Gynaecol 2005;112:228–233.
   Google Scholar
• Kenemans P, Kubista E, Foidart JM, Yip CH, Von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Beckmann MW, Bundred NJ, Egberts J, et al Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients – design and baseline data ‘LIBERATE’ trial. Breast 2007;16:S182–S189.
   Google Scholar